JNJ Johnson & Johnson - Fundamental Analysis
NEUTRAL
JNJ Stock | Fundamental Analysis & Investment Insights
NYSE
•
Healthcare
•
Drug Manufacturers - General
Current Price
$207.35
Analyst Target
$210.13
+1.3% Upside
52W High
$215.19
52W Low
$140.68
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
Johnson & Johnson's Advanced Deterministic Scorecard reveals a weak Piotroski F-Score of 3/9, indicating poor financial health based on fundamental signals, while the Altman Z-Score is astronomically high at 796972432179.2, suggesting a statistical anomaly or data error but technically implying no distress risk. Despite strong profitability metrics like a 33.62% ROE and 27.26% profit margin, the low Piotroski score, deteriorating technical trend (10/100), and bearish insider activity weigh heavily. The stock trades above its Graham Number of $87.59 at $207.35, but below the analyst target of $210.13, with solid earnings growth of 91% YoY likely driving valuation. However, weak liquidity (Quick Ratio: 0.71) and lack of key financial data (e.g., cash, debt, EV) limit confidence in stability.
Key Strengths
Exceptionally high Altman Z-Score, indicating negligible bankruptcy risk despite data irregularity
Strong profitability with ROE of 33.62%, ROA of 8.26%, and gross margin of 68.36%
Robust year-over-year earnings growth of 91.00% and consistent earnings beat history (22 of 25 quarters)
Attractive dividend yield of 2.51% with a sustainable 49.08% payout ratio
Analyst consensus supports a 'buy' recommendation with a target price of $210.13
Key Risks
Very low Piotroski F-Score of 3/9, signaling weak financial health and potential operational deterioration
Poor liquidity position with a Current Ratio of 1.07 and Quick Ratio of 0.71, below safe thresholds
Bearish technical trend (10/100) and recent price stagnation (1M change: +1.0%, 1W: -0.1%)
Significant insider selling: $42.88M in sales over last 6 months with zero buys, indicating lack of confidence
Missing critical financial data (Enterprise Value, Total Debt, Cash, ROIC, FCF) raises transparency concerns
AI Fair Value Estimate
Based on comprehensive analysis
$207.5
+0.1% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare JNJ against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations